Pilot Study to Assess the Efficacy of Botulinum Toxin B on Pain and Disability in Subjects With Acute Low Back Pain

Low Back Pain Clinical Trial

Official title:

Pilot Study to Assess the Efficacy of Botulinum Toxin B (Myobloc®) Treatment of Paravertebral Muscles on Pain and Disability in Subjects Suffering From Acute Low Back Pain

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00384579
• Other study ID #: DCI P05-71031
• Status: Terminated
• Phase: Phase 4
• First received: October 4, 2006
• Last updated: March 1, 2010
• Start date: February 2008
• Est. completion date: August 2010

Study information

• Verified date: February 2010
• Source: Walter Reed Army Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

This study will test the hypothesis that Botulinum toxin B (Myobloc®) treatment reduces pain and disability in subjects suffering from acute low back pain due to an identifiable muscle strain or back trauma occurring 3 to 6 weeks prior to enrollment. The study will also delineate the duration of medication effect and control for any placebo or mechanical trigger-point injection effect by employing a prospective, double-blind, placebo-controlled design.

Description:

This study will assess the efficacy of Botulinum Toxin B (Myobloc®) injected into the lumbar paravertebral muscles for reducing pain and disability in subjects suffering from acute low back pain (duration 3 to 6 weeks) arising from an identifiable muscle strain injury or back trauma. The treatment modality and techniques used are based upon three successful prior open-labeled pilot studies done by this research group investigating the effect of Botulinum Toxin A (BOTOX®) on relief of chronic low back pain. This study, however, will employ a prospective, double-blind, randomized, placebo controlled trial to control for any placebo or mechanical trigger-point injection effects. Subjects will also be assessed for 3 months to define the duration of efficacy of Myobloc®. Sixty subjects will be randomly assigned to one of two groups and will then receive either Myobloc® or placebo injection into the lumbar paravertebral muscles. The subjects will be assessed using validated scales for pain and disability prior to injection and weekly to monthly thereafter for three months. All subjects will continue to receive any medication or physiotherapy per standard of care but those treatments will be recorded and controlled for in the data analysis.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 0
• Est. completion date: August 2010
• Est. primary completion date: August 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Male or female subjects, 18 to 60 years of age, active duty military, retired military or other DOD beneficiaries eligible for care at military treatment facilities.

• Written informed consent and written authorization for use or release of health and research study information.

• Clear history of an identifiable muscle strain or trauma preceding the onset of low back pain.

• No prior history of vertebral disk disease/condition, sciatica or radiculopathy.

• Normal neurological examination without evidence of radiculopathy.

• Evidence of trigger point tenderness or muscle spasm upon palpation or EMG findings of muscle spasm.

• History of low back pain lasting 3 to 6 weeks from the time of injury or strain.

• VAS score minimum of 5 cm at time of entry into study.

• Ability to follow study instructions and likely to complete all required visits.

• Negative urine pregnancy test prior to the administration of study medication (for females of childbearing potential) (if applicable).

Exclusion Criteria:

• Age less than 18 or greater than 60.

• Not active duty.

• Concomitant use of aminoglycoside antibiotics, curare-like agents, or other agents that might interfere with neuromuscular function.

• Any medical condition that may put the subject at increased risk with exposure to Myobloc®, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis/motor neuron disease, neuropathy, renal stones, or any other disorder that might interfere with neuromuscular function or produce a similar type of low back pain.

• Females who are pregnant, breast-feeding, or planning a pregnancy during the study, or who think that they may be pregnant at the start of the study, or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study.

• Known allergy or sensitivity to any of the components in the study medication.

• Evidence of alcohol or substance abuse in 6 months prior to enrollment.

• Systemic medical conditions (such as thyroid disease, hypertension, bleeding disorders, diabetes, cancers, etc.) that are not currently medically managed or controlled.

• Concurrent participation in another investigational drug or device study or participation in the 30 days immediately prior to study enrollment.

• Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.

• Significant Axis I or II diagnosis determined by a neurologist or psychiatrist in the 6 months prior to entry into the study.

• Duration of low back pain < 3 weeks or > 6 weeks.

• Thoracic or cervical spine pain in the absence of acute low back pain.

• Anesthetic or corticosteroid injection to the lumbosacral spine within 8 weeks of enrollment.

• Spine MRI (any region) positive for acute pathology or evidence of radiculopathy on neurological examination.

• History of back surgery within one year or incomplete resolution of back pain due to a previous injury or surgery.

• Subjects involved in litigation, seeking significant disability for low back pain, or with evident secondary gain as determined by the neurologist through chart review and subject interview.

• Any previous use of Myobloc®, Dysport®, or BOTOX®.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Back Pain
• Low Back Pain

Intervention

Drug:
• Botulinum toxin B
Botulinum Toxin B
• Placebo
Placebo

Locations

Country	Name	City	State
United States	Walter Reed Army Medical Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
United States Department of Defense

Country where clinical trial is conducted

United States, 

References & Publications (7)

Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol. 2001 Apr;248 Suppl 1:3-10. Review. — View Citation

Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005 Oct;26(5):785-93. Epub 2005 Jul 5. Review. — View Citation

Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001 May 22;56(10):1290-3. — View Citation

Frymoyer JW. Predicting disability from low back pain. Clin Orthop Relat Res. 1992 Jun;(279):101-9. Review. — View Citation

Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology. 2000;55(12 Suppl 5):S29-35. — View Citation

Rand MJ, Whaler BC. Impairment of sympathetic transmission by botulinum toxin. Nature. 1965 May 8;206(984):588-91. — View Citation

Wipf JE, Deyo RA. Low back pain. Med Clin North Am. 1995 Mar;79(2):231-46. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Significant improvement in lower back pain		8 weeks	No
Secondary	Significant reduction of long term disability		12 weeks	No